
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
BioAge Labs, Inc (BIOA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BIOA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -6.07% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 674.12M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 2.88 - 26.62 | Updated Date 05/15/2025 |
52 Weeks Range 2.88 - 26.62 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 539045726 | Price to Sales(TTM) - |
Enterprise Value 539045726 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34167200 | Shares Floating 1177831 |
Shares Outstanding 34167200 | Shares Floating 1177831 | ||
Percent Insiders 3.8 | Percent Institutions 32.64 |
Upturn AI SWOT
BioAge Labs, Inc
Company Overview
History and Background
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat aging-related diseases. Founded in 2015, it leverages a data-driven approach to identify targets and develop therapeutics that can extend healthy lifespan.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and validating drug targets based on human aging data.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Licensing: Collaborates with other companies and institutions to advance its pipeline and expand its reach.
Leadership and Structure
BioAge is led by Kristen Fortney, PhD (CEO) and Eric Morgen, MD (CMO). The organizational structure includes teams dedicated to drug discovery, clinical development, and business development.
Top Products and Market Share
Key Offerings
- BGE-1750 (azelaprag): A prolyl endopeptidase inhibitor being developed for muscle aging and other age-related conditions. Currently in Phase 2 clinical trials. Market share is not yet applicable as the product is not approved for sale. Competitors include companies developing muscle-building or anti-aging therapies, such as Juvenescence and Alkahest.
- BGE-117 (apabetalone): A BET inhibitor being investigated for COVID-19 and aging-related diseases, in a prior collaboration with Resverlogix. Market share is not yet applicable as the product is not approved for sale. Resverlogix holds the IP and Bioage licensed it for aging related indications.
Market Dynamics
Industry Overview
The anti-aging industry is rapidly growing, driven by increasing life expectancy and a desire to maintain healthspan. The industry encompasses pharmaceuticals, supplements, diagnostics, and lifestyle interventions.
Positioning
BioAge is positioned as a leader in data-driven drug discovery for aging-related diseases, leveraging its proprietary human aging database to identify promising drug targets. Its competitive advantage lies in its focus on validated human targets.
Total Addressable Market (TAM)
The TAM for anti-aging therapeutics is estimated to be in the hundreds of billions of dollars, and is expected to continue to grow significantly in the coming years as the global population ages. BioAge is positioned to capture a portion of this market with its pipeline of therapies.
Upturn SWOT Analysis
Strengths
- Proprietary human aging database
- Experienced management team
- Strong intellectual property portfolio
- Focus on validated human targets
- Collaboration with reputable institutions
Weaknesses
- Limited clinical trial data
- Dependence on funding
- High drug development costs
- Regulatory hurdles
- Limited marketed products
Opportunities
- Expanding clinical trial pipeline
- Partnerships with pharmaceutical companies
- Acquisition of complementary technologies
- Growing anti-aging market
- Increasing acceptance of aging as a treatable condition
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory delays
- Changes in healthcare policy
- Ethical concerns related to anti-aging interventions
Competitors and Market Share
Key Competitors
- LLY
- NVO
- ABBV
- GILD
Competitive Landscape
BioAge competes with both established pharmaceutical companies and other biotech companies developing anti-aging therapies. Its advantages include its data-driven approach and focus on validated human targets. Disadvantages include it's current private status and lack of revenue generating product.
Growth Trajectory and Initiatives
Historical Growth: BioAge has grown significantly since its founding, expanding its pipeline of drug candidates and securing funding through venture capital. Growth trajectory is high but is still at an early stage.
Future Projections: Future growth is expected to be driven by the advancement of its clinical trials, partnerships, and potential acquisitions. Analyst estimates are not publicly available due to its private status.
Recent Initiatives: Recent initiatives include securing funding for Phase 2 trials of BGE-1750 and expanding its collaborations with research institutions. They have added data and targets to their Discovery program.
Summary
BioAge Labs, Inc. is a promising biotechnology company with a unique approach to developing anti-aging therapies. Its data-driven drug discovery platform and focus on validated human targets position it well for future growth. Key strengths include its proprietary database and experienced management team. However, the company faces challenges related to clinical trial risks, regulatory hurdles, and competition from larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioAge Labs, Inc. website
- Company press releases
- Third-party industry reports and analysis
- SEC filings of key competitors
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximations based on available data and may not be precise. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioAge Labs, Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2024-09-26 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Kristen Fortney Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 62 | Website https://bioagelabs.com |
Full time employees 62 | Website https://bioagelabs.com |
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.